Key Takeaways:
AdaptHealth Corp. shares plunged 38% to US$6.71 after the home medical equipment provider cut full-year adjusted EBITDA guidance and posted a wider-than-expected loss, overshadowing revenue of US$740.3 million.
Management framed the quarter as a cost of scaling, citing the myAPP platform's 512,000 users and early traction from an AI mask-fitting tool as adoption milestones on the Aug. 4 earnings call, even as adjusted EBITDA margin slipped to 17.8 percent.
Revenue of US$740.3 million came in roughly 13 percent below the US$847 million to US$849 million analysts expected, while the GAAP loss of US$0.99 a share reversed a consensus call for a loss near US$0.15. Adjusted EBITDA of US$132 million missed the roughly US$160 million forecast. Free cash flow swung to a US$20.9 million loss on US$166.2 million of capital spending tied largely to the West Coast contract, and the company booked a US$144.2 million goodwill impairment.
The reset cuts to the heart of AdaptHealth's strategy. The company is leaning into a higher-risk capitated revenue model — capitated revenue reached US$103.3 million, about 14 percent of continuing revenue — while carrying heavier leverage. A US$55 million guidance downgrade tied to the West Coast contract and a US$30 million hit from a manufacturer price spike raise whether the profit squeeze is a passing execution issue or a structural warning.
The bullish case rests on the idea that capitated contracts, technology, and focused M&A can build a recurring-revenue engine with better margins over time. Sleep Health and Respiratory Health together delivered double-digit revenue growth in the quarter, and capitated revenue's climb to 14 percent of continuing revenue supports the view that the model is scaling. The myAPP platform and AI mask-fitting tool are cited as evidence of digital adoption.
The bearish case reads the same numbers differently. The pivot to capitated revenue, heavy capital spending, and reimbursement pressure could lock the company into weaker margins and thinner free cash flow than the story promised. The US$55 million guidance cut, the US$30 million manufacturer price hit, and the US$144.2 million goodwill impairment are concrete milestones missed, and the 38 percent share drop after the print suggests the market sees the profitability and execution worries as confirmed rather than disproved.
AdaptHealth's balance sheet adds to the risk. The company is carrying heavier leverage as it funds the West Coast contract ramp and the capitated model build-out, and the negative free cash flow of US$20.9 million means it is spending more than it generates. In the broader home medical equipment sector, peers face similar reimbursement pressure, but AdaptHealth's concentrated bet on capitated contracts makes it more exposed to execution risk.
AdaptHealth has also been reshaping its portfolio. On July 20, it agreed to divest its Diabetes Health business to Cardinal Health, and on July 7 it disclosed that patient data was stolen in a June cyberattack. The company is scheduled to participate in upcoming investor conferences in August.
The latest drop extends a difficult stretch. Shares are down about 11 percent since the start of the year and sit well below the 52-week high of US$11.38 reached in February 2025. The prior quarter told a similar story: AdaptHealth fell 16.4 percent after its fourth-quarter 2025 report, when a GAAP loss of US$0.76 a share and an operating margin that contracted to negative 8.7 percent overshadowed revenue of US$846.3 million.
The next test comes with the full-year outlook. If the West Coast contract ramp and capitated model translate into cleaner margins and positive free cash flow in the second half, the reset may prove a one-time cost. If not, the leverage and margin pressure could keep the stock under pressure into 2027.
This article is for informational purposes only and does not constitute investment advice.
